Call for GSK Trizivir withdrawal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The AIDS Healthcare Foundation is asking FDA to remove GlaxoSmithKline's HIV triple-combination therapy Trizivir (abacavir/lamivudine/zidovudine) from the market based on results from a 1,147-patient NIH study (ACTG 5095) comparing Trizivir alone to Trizivir plus Bristol's Sustiva or Sustiva (efavirenz) plus GSK's Combivir (zidovudine/lamivudine) in first-line patients. NIH suspended the Trizivir-only arm in March after findings of virologic failure "sooner and more often" than the other two arms (1Pharmaceutical Approvals Monthly April 1, 2003, p. 6). AHF claims that GSK continues to "aggressively market the questionable regimen." GSK issued a "Dear Doctor" letter in July warning against use of its Ziagen (abacavir) and Epivir (lamivudine) with Gilead's Viread (tenofovir) in treatment-naïve and -experienced patients...
You may also be interested in...
Trizivir-Alone Arm Of NIH Trial Halted Due To Greater Effect In Sustiva Combos
First-line use of GlaxoSmithKline’s Trizivir is inferior to two treatment regimens containing Bristol-Myers Squibb’s Sustiva, according to interim results of a 1,147-patient NIH study of protease-inhibitor-sparing regimens for initial treatment of HIV.
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continue, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.